NWBO's Mounting Losses Raise Going Concern Doubts Amid Acquisition

TL;DR

**NWBO is burning cash and facing a going concern warning; this stock is a high-risk bet on future regulatory approval, not current fundamentals.**

AI Summary

NORTHWEST BIOTHERAPEUTICS INC reported a net loss of $61.55 million for the nine months ended September 30, 2025, an increase from $55.55 million for the same period in 2024. The company's revenue from research and other activities decreased to $706,000 for the nine months ended September 30, 2025, down from $1.15 million in the prior year. Operating costs and expenses also saw a slight decrease, totaling $47.12 million for the nine months ended September 30, 2025, compared to $49.16 million in 2024. Cash and cash equivalents increased to $4.56 million as of September 30, 2025, from $2.18 million at December 31, 2024, primarily due to $35.74 million in financing activities. A significant business change includes the agreement to acquire Advent BioServices Ltd, a related party CDMO, which closed on October 24, 2025. The company faces substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash flow deficits, having used $30 million in operating cash during the nine-month period. Strategic outlook focuses on regulatory approval for DCVax-L in the U.K. and restarting the DCVax-Direct program.

Why It Matters

This filing reveals NORTHWEST BIOTHERAPEUTICS INC's precarious financial position, with a substantial doubt about its ability to continue as a going concern. For investors, this signals high risk and potential for significant dilution or even bankruptcy if additional financing isn't secured on favorable terms. Employees face job insecurity given the company's reliance on external funding and lack of material revenue. Customers and the broader market, particularly those awaiting DCVax-L for glioblastoma, face uncertainty regarding product availability and the company's long-term viability, especially as competitors in the oncology space continue to advance. The acquisition of Advent BioServices Ltd, a related party, could be seen as an attempt to consolidate operations but also adds to the financial burden.

Risk Assessment

Risk Level: high — The company explicitly states "there is substantial doubt about the Company's ability to continue as a going concern for at least one year from the date of this filing" due to recurring operating losses and operating cash flow deficits. NWBO incurred a net loss of $61.55 million and used $30 million in cash from operations for the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit going concern warning and significant cash burn, new investors should avoid NWBO, while existing investors should re-evaluate their position, understanding the high risk of further dilution or capital loss.

Financial Highlights

debt To Equity

N/A

revenue

$706,000

operating Margin

N/A

total Assets

$30.61 million

total Debt

$125.86 million

net Income

-$61.55 million

eps

N/A

gross Margin

N/A

cash Position

$4.56 million

revenue Growth

-38.6%

Revenue Breakdown

Key Numbers

• $61.55M — Net Loss (Increased from $55.55M in prior year, indicating worsening financial performance.)
• $706K — Total Revenues (Decreased from $1.15M, showing a decline in minimal revenue streams.)
• $30M — Cash Used in Operating Activities (Significant cash burn for the nine months ended September 30, 2025.)
• $4.56M — Cash and Cash Equivalents (Low cash balance relative to burn rate, despite increase from financing.)
• $125.86M — Total Liabilities (Increased from $105.71M, indicating growing financial obligations.)
• $108.65M — Total Stockholders' Deficit (Worsened from $94.49M, reflecting accumulated losses.)
• 1,540,682,082 — Common Stock Shares Outstanding (High share count as of November 13, 2025, indicating potential for significant dilution.)
• $35.74M — Net Cash Provided by Financing Activities (Crucial for funding operations, but unsustainable long-term without product revenue.)

Key Players & Entities

• NORTHWEST BIOTHERAPEUTICS INC (company) — registrant
• Advent BioServices Ltd (company) — acquired contract development and manufacturing organization (CDMO)
• Medicines and Healthcare Products Regulatory Agency (MHRA) (regulator) — reviewing MAA for DCVax-L in the U.K.
• $61.55 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $55.55 million (dollar_amount) — net loss for nine months ended September 30, 2024
• $706,000 (dollar_amount) — total revenues for nine months ended September 30, 2025
• $1.15 million (dollar_amount) — total revenues for nine months ended September 30, 2024
• $30 million (dollar_amount) — cash used in operating activities for nine months ended September 30, 2025
• $4.56 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $2.18 million (dollar_amount) — cash and cash equivalents as of December 31, 2024

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company faces substantial doubt about its ability to continue as a going concern due to recurring operating losses and cash flow deficits. During the nine months ended September 30, 2025, the company used $30 million in operating cash, highlighting a significant cash burn rate relative to its available cash position.
• Increasing Liabilities [high — financial]: Total liabilities increased from $105.71 million as of December 31, 2024, to $125.86 million as of September 30, 2025. This rise, particularly in current liabilities like accounts payable and accrued expenses, indicates growing financial obligations and potential liquidity pressures.
• Deteriorating Stockholders' Deficit [high — financial]: The total stockholders' deficit worsened from $94.49 million at the end of 2024 to $108.65 million by September 30, 2025. This deterioration is driven by accumulated operating losses, reflecting the company's ongoing unprofitability.
• Dependence on Financing Activities [high — operational]: The company's cash position increased to $4.56 million from $2.18 million primarily due to $35.74 million in financing activities. This heavy reliance on external financing for operations is unsustainable long-term without generating substantial product revenue.
• Regulatory Approval Dependency [high — regulatory]: The company's strategic outlook is heavily dependent on regulatory approval for DCVax-L in the U.K. and the restart of the DCVax-Direct program. Delays or failures in obtaining these approvals could severely impact future revenue generation and operational viability.
• Low Revenue Generation [medium — financial]: Revenue from research and other activities has declined to $706,000 for the nine months ended September 30, 2025, down from $1.15 million in the same period last year. This minimal revenue stream is insufficient to cover operating expenses.
• Related Party Transactions [medium — financial]: The acquisition of Advent BioServices Ltd, a related party CDMO, closed on October 24, 2025. While intended to enhance capabilities, related party transactions can introduce complexities and potential conflicts of interest that require careful management and disclosure.
• Dilution Risk [medium — financial]: With 1,540,682,082 common stock shares outstanding as of November 13, 2025, the company has a high share count. Future financing needs or conversion of outstanding debt/equity instruments could lead to significant dilution for existing shareholders.

Industry Context

The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on external financing and strategic partnerships to fund operations until a product achieves market approval and generates revenue. The market for advanced therapies, like Northwest Biotherapeutics' potential cancer treatments, is competitive and requires substantial clinical validation.

Regulatory Implications

The company's future hinges on successful regulatory approvals, particularly for DCVax-L in the U.K. Any delays or rejections from regulatory bodies like the EMA or FDA would severely impact its ability to commercialize its products and achieve financial stability. Compliance with manufacturing standards (e.g., GMP) is also critical for any approved therapies.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-10-24: Acquisition of Advent BioServices Ltd closed — This acquisition of a related party CDMO is a significant strategic move, aiming to integrate critical manufacturing capabilities, but introduces complexities related to related-party transactions.
• 2025-09-30: Nine months ended financial statements filed — Provides a snapshot of the company's financial performance and condition, highlighting a net loss of $61.55 million and a significant cash burn of $30 million from operations.
• 2025-12-31: Previous fiscal year end — Provides a comparative baseline for the current period's financial results, showing total liabilities of $105.71 million and a stockholders' deficit of $94.49 million.

Glossary

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The company explicitly states substantial doubt about its ability to continue as a going concern, indicating significant financial distress.)

CDMO

Contract Development and Manufacturing Organization. A company that provides services for drug development and manufacturing on a contract basis. (The acquisition of Advent BioServices Ltd, a CDMO, is a key strategic event for Northwest Biotherapeutics, aiming to bolster its manufacturing capabilities.)

Stockholders' Deficit

Occurs when a company's total liabilities exceed its total assets, resulting in a negative equity position. (Northwest Biotherapeutics has a substantial and growing stockholders' deficit ($108.65 million as of Sept 30, 2025), indicating accumulated losses.)

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income or capital contributions. (The company's accumulated deficit stands at $1.505 billion as of September 30, 2025, underscoring its long-term unprofitability.)

Convertible Notes

Debt instruments that can be converted into shares of the issuing company's stock under certain conditions. (The company has significant amounts of convertible notes, both at fair value and net of current portion, which represent potential future equity dilution.)

Mezzanine Equity

A class of equity that has characteristics of both debt and equity, often with a liquidation preference over common stock. (The company has Series C Convertible Preferred Stock classified as mezzanine equity, with a liquidation preference of $11.7 million.)

Year-Over-Year Comparison

Compared to the prior year period, Northwest Biotherapeutics Inc. reported a wider net loss of $61.55 million for the nine months ended September 30, 2025, up from $55.55 million. Revenue from research and other activities also declined by 38.6% to $706,000. While operating costs saw a slight decrease, the overall financial performance has worsened. Total liabilities have increased significantly, and the stockholders' deficit has grown, underscoring the company's ongoing financial challenges and reliance on financing.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share NWBO OTCQB As of Novemb

Filing Documents

• nwbo-20250930x10q.htm (10-Q) — 2283KB
• nwbo-20250930xex31d1.htm (EX-31.1) — 14KB
• nwbo-20250930xex32d1.htm (EX-32.1) — 9KB
• 0001104659-25-112676.txt ( ) — 10374KB
• nwbo-20250930.xsd (EX-101.SCH) — 73KB
• nwbo-20250930_cal.xml (EX-101.CAL) — 59KB
• nwbo-20250930_def.xml (EX-101.DEF) — 316KB
• nwbo-20250930_lab.xml (EX-101.LAB) — 520KB
• nwbo-20250930_pre.xml (EX-101.PRE) — 436KB
• nwbo-20250930x10q_htm.xml (XML) — 2200KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Interim Financial Statements (Unaudited) Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Deficit for the three and nine months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 32 Item 4.

Controls and Procedures

Controls and Procedures 32

- OTHER INFORMATION

PART II - OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

SIGNATURES

SIGNATURES 36 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION NORTHWEST BIOTHERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 4,560 $ 2,175 Prepaid expenses and other current assets 2,327 1,887 Loan receivable 311 — Total current assets 7,198 4,062 Non-current assets: Property, plant and equipment, net 16,870 16,196 Right-of-use asset, net 4,265 4,187 Indefinite-lived intangible asset 1,292 1,292 Goodwill 626 626 Other assets 358 365 Total non-current assets 23,411 22,666 TOTAL ASSETS $ 30,609 $ 26,728 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses $ 26,875 $ 16,969 Accounts payable and accrued expenses to related parties and affiliates 9,841 4,452 Convertible notes, net 818 1,870 Convertible notes at fair value 26,008 18,324 Notes payable, net 13,570 14,186 Contingent payable derivative liability 9,665 9,578 Warrant liability — 2,219 Investor advances 207 207 Share payable 522 143 Lease liabilities 399 326 Total current liabilities 87,905 68,274 Non-current liabilities: Convertible notes at fair value, net of current portion 24,617 15,900 Notes payable, net of current portion, net 7,188 12,396 Lease liabilities, net of current portion 4,447 4,438 Contingent payment obligation 1,700 4,700 Total non-current liabilities 37,952 37,434 Total liabilities 125,857 105,708 COMMITMENTS AND CONTINGENCIES (Note 12) Mezzanine equity: Series C Convertible Preferred Stock, 10,000,000 shares designated; 0.8 million and 1.0 million shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $ 11.7 million 13,400 15,507 Stockholders' deficit: Preferre